Comparative Pharmacology
Head-to-head clinical analysis: OPTOMYCIN versus VASOCIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTOMYCIN versus VASOCIDIN.
OPTOMYCIN vs VASOCIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Optomycin is a semi-synthetic glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transpeptidation and cross-linking.
Vasocidin is a combination of sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial growth, and prednisolone sodium phosphate, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and subsequent prostaglandin and leukotriene synthesis.
1.5 mg/kg IV every 8 hours; alternatively, 5-7 mg/kg IV daily.
One drop of the ophthalmic suspension into the conjunctival sac of the affected eye(s) every 4 hours while awake and at bedtime for 7 days; duration may be extended based on clinical response.
None Documented
None Documented
3-5 hours (terminal half-life); prolonged to 10-20 hours in renal impairment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment.
Renal: 75-90% unchanged; biliary: 5-10%; fecal: <5%.
Renal: 70-80% as unchanged drug; biliary/fecal: 20-30% as metabolites and unchanged drug.
Category C
Category C
Ophthalmic Antibiotic/Corticosteroid Combination
Ophthalmic Antibiotic/Corticosteroid Combination